AKT1 and Cognitive impairment: In recent years, studies have shown that the CB2R agonist exhibits a neuroprotective effect in the CNS by activating the PI3K/Akt signaling pathway [42], which reduces cognitive impairment, increases cerebral blood flow, and inhibits neuronal apoptosis in an animal model of VD [43].